Linezolid resistance in a clinical isolate of Staphylococcus aureus
S Tsiodras, HS Gold, G Sakoulas, GM Eliopoulos… - The Lancet, 2001 - thelancet.com
S Tsiodras, HS Gold, G Sakoulas, GM Eliopoulos, C Wennersten, L Venkataraman…
The Lancet, 2001•thelancet.comThe new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of
infections caused by various gram-positive bacteria, including meticillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although
instances of linezolid resistance in VRE have been reported, resistance has not been
encountered among clinical isolates of S aureus. We have characterised an MRSA isolate
resistant to linezolid that was recovered from a patient treated with this agent for dialysis …
infections caused by various gram-positive bacteria, including meticillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although
instances of linezolid resistance in VRE have been reported, resistance has not been
encountered among clinical isolates of S aureus. We have characterised an MRSA isolate
resistant to linezolid that was recovered from a patient treated with this agent for dialysis …
Summary
The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.
thelancet.com